Methods of vaccine administration

Abstract

This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

1 . A method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally in a first dose, orally in a second dose, orally in an optional third dose, and orally in one or more annual doses, and wherein the viral antigens comprise one or more of 1) canine distemper (CD) virus, 2) canine adenovirus type 2 (CAV-2), 3) canine parainfluenza (CPI) virus, 4) canine parvovirus (CPV), 5) and canine coronavirus (CCV), and wherein the bacterin comprises one or more bacteria selected from  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona, L. bratislava,  and  Bordetella bronchiseptica ; and any combination of viral antigens and bacteria thereof. 
   
   
       2 . (canceled) 
   
   
       3 . A method according to  claim 1 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV. 
   
   
       4 . A method according to  claim 1 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV, and the bacteria in the bacterin are  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae,  and  L. pomona.    
   
   
       5 . A method according to  claim 1 , wherein the viral antigens are CD virus, CAV-2, CPI virus, CPV, and CCV, and the bacteria in the bacterin are  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae  and  L. pomona.    
   
   
       6 . A method according to  claim 1 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV, and the bacterium in the bacterin is  Bordetalla bronchiseptica.    
   
   
       7 . A method according to  claim 1 , wherein the canine diseases comprise one or more of 1) CD caused by CD virus; 2) infectious canine hepatitis caused by CAV-1; 3) respiratory disease caused by CAV-2 or respiratory CCV; 4) CPI caused by CPI virus; 5) enteritis caused by CCV or CPV; 6) leptospirosis caused by  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona , or  L. Bratislava ; and 7) infectious tracheobronchitis (“kennel cough”) caused by  Bordetella bronchiseptica.    
   
   
       8 . A method according to  claim 7 , wherein the diseases comprise 1) CD caused by CD virus; 2) infectious canine hepatitis caused by CAV-1; 3) respiratory disease caused by CAV-2; 4) CPI caused by CPI virus; 5) and canine parvoviral enteritis caused by CPV. 
   
   
       9 . A method according to  claim 1 , wherein the viral antigens are present in the following ranges of amounts: for CD virus, about 102 TCID 50  to about 10 8  TCID 50 , inclusive; for CAV-2, about 10 2  TCID 50  to about 10 8  TCID 50 , inclusive; for CPV, about 10 3  TCID 50  to about 10 10  TCID 50 , inclusive; for CPI virus, about 10 3  TCID 50  to about 10 10  TCID 50 , inclusive; and for CCV, at least about 100 relative units (RU) per dose. 
   
   
       10 . (canceled) 
   
   
       11 . (canceled) 
   
   
       12 . A method according to  claim 1 , wherein each  Leptospira  is present in a range of amounts from about 100 nephelometric units (NU) to about 3,500 NU per vaccine dose, and wherein the  Bordetella bronchiseptica  is present in a range from about 3×10 6  to about 3×10 11  cells inclusive. 
   
   
       13 . (canceled) 
   
   
       14 . (canceled) 
   
   
       15 . A method according to  claim 1 , wherein the second dose is administered from 7 to 35 days, inclusive, after the first dose. 
   
   
       16 . (canceled) 
   
   
       17 . A method according to  claim 1 , wherein the third dose is administered from 7 to 35 days, inclusive, after the second dose. 
   
   
       18 . (canceled) 
   
   
       19 . A method according to  claim 1 , wherein a first annual dose is administered about one year after the first dose. 
   
   
       20 . A method according to  claim 19 , wherein annual doses administered after said first annual dose are administered repeatedly about one year after the immediately prior annual dose. 
   
   
       21 . A method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously in a first and in a second dose, and orally in a third dose, and orally in one or more annual doses, and wherein the viral antigens comprise one or more of 1) CD virus, 2) CAV-2, 3) CPI virus, 4) CPV, 5) and CCV, and the bacterin comprises one or more bacteria selected from  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona, L. bratislava,  and  Bordetella bronchiseptica;  and any combination of viral antigens and bacteria thereof. 
   
   
       22 . A method according to  claim 21 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV. 
   
   
       23 . A method according to  claim 21 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV, and the bacteria in the bacterin are  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae,  and  L. pomona.    
   
   
       24 . A method according to  claim 21 , wherein the viral antigens are CD virus, CAV-2, CPI virus, CPV, and CCV, and the bacteria in the bacterin are  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae,  and  L. pomona.    
   
   
       25 . A method according to  claim 21 , wherein the viral antigens are CD virus, CAV-2, CPI virus, and CPV, and the bacterium in the bacterin is  Bordetella bronchiseptica.    
   
   
       26 . A method according to  claim 21 , wherein the canine diseases comprise one or more of 1) CD caused by CD virus; 2) infectious canine hepatitis caused by CAV-1; 3) respiratory disease caused by CAV-2 or respiratory CCV; 4) CPI caused by CPI virus; 5) enteritis caused by CCV or CPV; 6) leptospirosis caused by  Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona,  or  L. Bratislava;  and 7) infectious tracheobronchitis (“kennel cough”) caused by  Bordetella bronshiseptica.    
   
   
       27 . A method according to  claim 26 , wherein the diseases comprise 1) CD caused by CD virus; 2) infectious canine hepatitis caused by CAV-1; 3) respiratory disease caused by CAV-2; 4) CPI caused by CPI virus; 5) and canine parvoviral enterits caused by CPV. 
   
   
       28 . A method according to  claim 21 , wherein the viral antigens are present in the following ranges of amounts: for CD virus, about 10 2  TCID 50  to about 10 8 TCID 50 , inclusive; for CAV-2, about 10 2  TCID 50  to about 10 8  TCID 50 , inclusive; for CPV, about 10 3  TCID 50  to about 10 10  TCID 50 , inclusive; for CPI virus, about 10 10  TCID 50 , to about 10 10  TCID 50 , inclusive; and for CCV, at least about 100 relative units (RU) per dose. 
   
   
       29 . A method according to  claim 21 , wherein each Leptospira is present in a range of amounts from about 100 nephelometric units (NU) to about 3,500 NU per vaccine dose, and wherein the  Bordetella bronchiseptica  is present in a range from about 3×10 6  to about 3×10 11  cells inclusive. 
   
   
       30 . A method according to  claim 21 , wherein the second dose is administered from 7 to 35 days, inclusive, after the first dose. 
   
   
       31 . A method according to  claim 21 , wherein the third dose is administered from 7 to 35 days, inclusive, after the second dose. 
   
   
       32 . A method according to  claim 21 , wherein a first annual dose is administered about one year after the first dose. 
   
   
       33 . A method according to  claim 32 , wherein annual doses administered after said first annual dose are administered repeatedly about one year after the immediately prior annual dose,